Research progress of effect of neutrophil elastase and its inhibitors in sepsis
Sepsis is a clinical syndrome of life-threatening organ dysfunction caused by infection. When an infection occurs, as the first line of defense of the body's immune system, neutrophils are first recruited to the site of infection to capture and kill pathogens by releasing neutrophil elastase (NE). However, a large amount of NE release will injury the surrounding normal tissues and induce organ dysfunction or failure. NE inhibitors can inhibit NE activity and reduce inflammatory response, which may be a promising drug for the treatment of sepsis. Currently, a variety of NE inhibitors have been developed and reported, but there is no systematic overview of their characteristics, and the role and underlying mechanisms of NE and related inhibitors in sepsis have not been thoroughly discussed. This article will make a review in this regard, in order to elucidate the effect of NE and its inhibitors in sepsis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Zhonghua wei zhong bing ji jiu yi xue - 34(2022), 11 vom: 01. Nov., Seite 1209-1212 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Yao, Lu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 3.4.21.37 |
|---|
| Anmerkungen: |
Date Completed 20.01.2023 Date Revised 20.01.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn121430-20220419-00389 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350790590 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350790590 | ||
| 003 | DE-627 | ||
| 005 | 20231226045809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn121430-20220419-00389 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350790590 | ||
| 035 | |a (NLM)36567568 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Yao, Lu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Research progress of effect of neutrophil elastase and its inhibitors in sepsis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.01.2023 | ||
| 500 | |a Date Revised 20.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Sepsis is a clinical syndrome of life-threatening organ dysfunction caused by infection. When an infection occurs, as the first line of defense of the body's immune system, neutrophils are first recruited to the site of infection to capture and kill pathogens by releasing neutrophil elastase (NE). However, a large amount of NE release will injury the surrounding normal tissues and induce organ dysfunction or failure. NE inhibitors can inhibit NE activity and reduce inflammatory response, which may be a promising drug for the treatment of sepsis. Currently, a variety of NE inhibitors have been developed and reported, but there is no systematic overview of their characteristics, and the role and underlying mechanisms of NE and related inhibitors in sepsis have not been thoroughly discussed. This article will make a review in this regard, in order to elucidate the effect of NE and its inhibitors in sepsis | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Leukocyte Elastase |2 NLM | |
| 650 | 7 | |a EC 3.4.21.37 |2 NLM | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 700 | 1 | |a Xu, Jiqian |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiaobo |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, You |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua wei zhong bing ji jiu yi xue |d 2013 |g 34(2022), 11 vom: 01. Nov., Seite 1209-1212 |w (DE-627)NLM226917215 |x 2095-4352 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2022 |g number:11 |g day:01 |g month:11 |g pages:1209-1212 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn121430-20220419-00389 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2022 |e 11 |b 01 |c 11 |h 1209-1212 | ||